PainChek General Discussion, page-17162

I don't think management is ignoring the SP per se. It is management speak when they say they are concentrating on the business, that is indirectly managing the share price too. After all, if they should manage to sign a significant deal with, say Philips or UK NHS, then won't the share price take care of itself? As for further funds, management is already smart enough to recognise that need and recently raised at 11 cents when the opportunity arise. And it was fully subscribed in next to no time at all. The smart cookies understand the business and believe in where it is going. And now, only time will tell the eventual outcome. But as with anything that involves time, only the patient holders who have done their research will hold unless something substantially negative happens. Meanwhile, those who rely on ramp or don't do their own research (weak hands) will start to flounder and sell cheaply to those who can't get enough at 11 cents. Hence the current share price. After all, nothing has changed since the raise.